Eli Lilly reveals two-year data for experimental eczema treatment after FDA roadblock
Eli Lilly is bolstering the case for its experimental eczema treatment lebrikizumab with a first look at how patients fared after two years of maintenance treatment.
Almost 80% of moderate-to-severe atopic dermatitis patients on once-monthly lebrikizumab maintained clear or almost clear skin at two years, Lilly announced on Friday. The safety profile was also “consistent with previous lebrikizumab studies in patients with moderate-to-severe atopic dermatitis” with no new signals seen, the company said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.